Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms. Cocrystals of cannabidiol and a coformer selected from L-proline, D-proline, tetramethylpyrazine, and 4,4?-dipyridyl are also disclosed herein.

Abstract: Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms. Cocrystals of cannabidiol and a coformer selected from L-proline, D-proline, tetramethylpyrazine, and 4,4?-dipyridyl are also disclosed herein.

Abstract: Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions.

Abstract: Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms.

Abstract: Provided is a sterile, injectable solution comprising: poloxamer 188 and water for injection, wherein the sterile, injectable solution is reduced in sodium and/or substantially sodium-free. Also provided are methods for using the solution.

Abstract: Provided methods of administering poloxamer 188 for treating heart failure by only a single short relatively high dose infusion, or by regimen that includes the single infusion followed by additional infusions at intervals of 1-4 weeks.

Abstract: Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions.

Abstract: Provided are uses of a poloxamer and methods of administering a poloxamer for treating hemo-concentration, such as hemo-concentration resulting from dehydration and/or diuresis in a subject. Administration of a poloxamer prevents, treats or otherwise reduces adverse effects of hemo-concentration, dehydration and/or diuresis.

Abstract: Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions.

Abstract: Provided are methods and uses of polyoxyethylene/polyoxypropylene copolymers (poloxamers) for treating bleeding and hemorrhage in animals, including human or veterinary subjects, and thus, treating hemostatic dysfunction, resulting from, for example, drug, disease-, trauma- or surgical-induced bleeding. Polyoxyethylene/polyoxypropylene copolymers improve hemostasis and aid in the control of bleeding. Methods for treating strokes using the polyoxyethylene/polyoxypropylene copolymers also are provided. Devices, products and compositions for treating or preventing hemostatic dysfunction are provided.

Abstract: Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions.

Abstract: Provided methods of administering poloxamer 188 for treating heart failure by only a single short relatively high dose infusion, or by regimen that includes the single infusion followed by additional infusions at intervals of 1-4 weeks.

Abstract: The present invention provides methods for preventing the adverse effects of transfusing a patient with blood or blood products compromised by storage lesion. The methods include administering to a patient a pharmaceutical composition comprising an effective amount of a polyoxyethylene/polyoxypropylene copolymer and a pharmaceutically acceptable carrier. The safety and effectiveness of transfusing blood with storage lesion can be increased using the methods of the invention.

Abstract: The present invention relates to compositions and methods for delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a delivery composition comprising an administerable admixture of an effective amount of a nucleic acid sequence and an effective amount of a surface active nonionic block copolymer having the following general formula: HO(C2H4O)b(C3H6O)a(C2H4O)bH wherein a is an integer such that the hydrophobe represented by (C3H6O) has a molecular weight between approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to approximately 25%.

Abstract: The present invention comprises novel polyoxyethylene/polyoxypropylene block copolymers compositions and compounds. The compositions comprise block copolymers that are useful in gene therapy methods.